InsidersTradesSigma
Mannkind CORP Stock: price and management transactions · United States · SEC (Form 4)
Follow the Mannkind CORP stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Mannkind CORP has published 165 public disclosures. Market capitalisation: €1.1bn. The latest transaction was filed on 22 May 2026 (Attribution). Among the most active insiders: Castagna Michael. The full history is accessible without an account.
165
Insider Decl.
0
Thresholds
€732,330
21 ops.
Buy Volume
€1m
17 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Mannkind CORP Strong Buy (bullish), based on 8 analysts. Average price target: US$7.59.
36Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 18,427 of 25,514 companies
36.9
score / 100
Value30
Quality44
FCF yld1.0%
Earn yld0.4%
EV/EBITDA32.4x
ROE·
Gross mgn75%
Net mgn1.7%
Debt/EBITDA7.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 22 May 2026
Declarations165 total
10,000 shares@ US$2.950.0027% mcap100.0% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-237444:0
5,190 shares@ US$4.370.5% of flowCommon Stock, $0.01 Par ValueSEC:0000950170-25-075536:0
9,536 shares@ US$4.371.4% of flowCommon Stock, $0.01 Par ValueSEC:0000950170-25-075534:0
26,114 shares@ US$4.371.4% of flowCommon Stock, $0.01 Par ValueSEC:0000950170-25-075538:0
6,147 shares@ US$4.370.7% of flowCommon Stock, $0.01 Par ValueSEC:0000950170-25-075540:0
27,000 shares@ US$4.561.5% of flowCommon Stock, $0.01 Par ValueSEC:0000950170-25-073801:0
25,000 shares@ US$4.5631.9% of flowCommon Stock, $0.01 Par ValueSEC:0000950170-25-073790:0
59,500 shares0Common Stock, $0.01 Par ValueSEC:0000950170-25-073800:0
298,560 shares0Common Stock, $0.01 Par ValueSEC:0000950170-25-073078:0
119,000 shares0Common Stock, $0.01 Par ValueSEC:0000950170-25-073049:0
119,000 shares0Common Stock, $0.01 Par ValueSEC:0000950170-25-073046:0
105,600 shares0Common Stock, $0.01 Par ValueSEC:0000950170-25-073081:0
105,600 shares0Common Stock, $0.01 Par ValueSEC:0000950170-25-073082:0
39,500 shares0Common Stock, $0.01 Par ValueSEC:0000950170-25-051315:0
16,407 shares@ US$5.1037.1% of flowCommon Stock, $.01 Par ValueSEC:0000950170-25-047092:0
103,600 shares0Common Stock, $.01 Par ValueSEC:0000950170-25-047091:0
252,000 shares0Common Stock, $0.01 Par ValueSEC:0000950170-25-020295:0
67,536 shares@ US$1.472.4% of flowCommon Stock, $0.01 Par ValueSEC:0000950170-24-130728:0
67,539 shares@ US$1.472.3% of flowCommon Stock, $0.01 Par ValueSEC:0000950170-24-128986:0
55,000 shares@ US$7.3410.6% of flowCommon Stock, $0.01 Par ValueSEC:0000950170-24-124349:0
17,071 shares@ US$7.0758.6% of flowCommon Stock, $0.01 Par ValueSEC:0000950170-24-121041:0
25,000 shares@ US$6.264.1% of flowCommon Stock, $0.01 Par ValueSEC:0000950170-24-103683:0
45,000 shares@ US$6.337.4% of flowCommon Stock, $0.01 Par ValueSEC:0000950170-24-102517:0
56,085 shares@ US$5.383.7% of flowCommon Stock, $0.01 Par ValueSEC:0000950170-24-102043:0
20,779 shares@ US$5.382.5% of flowCommon Stock, $0.01 Par ValueSEC:0000950170-24-102041:0
25 of 165 declarations
About Mannkind CORP
MannKind Corp. (ticker MNKD) is a U.S.-listed biopharmaceutical company traded on the Nasdaq in the United States. Founded in 1991 and currently headquartered in Danbury, Connecticut, the company focuses on developing and commercializing innovative therapeutic products and delivery devices aimed at serious chronic diseases. Its core strategy centers on cardiometabolic and orphan lung conditions, with manufacturing and technical operations anchored in Connecticut. ([investors.mannkindcorp.com](https://investors.mannkindcorp.com/investor-relations?utm_source=openai)) The company’s best-known asset is Afrezza®, an ultra rapid-acting inhaled human insulin used to improve glycemic control in adults with diabetes. MannKind also owns the Technosphere® platform, a proprietary inhalation technology that underpins several products and collaborations. That platform has been used in Tyvaso DPI®, a product commercialized by United Therapeutics for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. This gives MannKind a mix of direct product sales and royalty streams, which makes the business model more diversified than a single-product biotech story. ([mannkindcorp.com](https://mannkindcorp.com/about/?utm_source=openai)) In late 2025 and into 2026, MannKind’s commercial footprint expanded further with the addition of FUROSCIX, a marketed furosemide therapy for fluid overload related to heart failure or kidney disease, and with V-Go®, an insulin delivery device. Management has also highlighted near-term regulatory catalysts, including an Afrezza pediatric filing under FDA review, as well as pipeline programs such as MNKD-201 (nintedanib DPI) and other inhalation-based assets. In May 2026, the company announced a ralinepag DPI program with United Therapeutics, reinforcing the importance of strategic partnerships in MannKind’s growth profile. ([investors.mannkindcorp.com](https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-acquire-scpharmaceuticals-accelerating-revenue-growth?utm_source=openai)) From a competitive standpoint, MannKind is a specialized niche player rather than a large-cap pharmaceutical heavyweight. Its edge lies in inhalation science, differentiated drug-device combinations, and the ability to monetize partnered assets in areas where convenience, adherence, and patient experience matter. For investors, MNKD is best viewed as a commercial-stage biopharma with multiple operating levers, but still exposed to FDA timing risk, execution risk, and some revenue concentration. The recent business updates suggest a company trying to broaden its base of commercial assets while preserving optionality through pipeline development and external collaborations. ([investors.mannkindcorp.com](https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-provides-business-updates-and-2026-growth-drivers?utm_source=openai))
